Where does Stephen Knight work?

Stephen Knight is President and Managing Partner at F-Prime Capital and Board director at Ensoma and Board director at Sana Biotechnology and Board director at Beam Therapeutics.

What check size does Stephen Knight write?

Stephen Knight typically writes checks of $100K – $10M.

What boards does Stephen Knight sit on?

Stephen Knight holds tracked board seats at Ensoma.

Where did Stephen Knight go to school?

Stephen Knight studied at Yale School of Medicine (MD); Yale School of Management (MBA); Columbia University (BS, Biology).

Stephen Knight

Investor

President and Managing Partner at F-Prime Capital · Board director at Ensoma · Board director at Sana Biotechnology · Board director at Beam Therapeutics

Cambridge, Massachusetts

Writes $100K – $10M checks · typically $5M

Find your path to Stephen

349 people in our graph share verified history with Stephen — schools, employers, funds. One of them is your warm intro.

Scott BillerunlockedStephen: together at Columbia University (1982–1983)

Stephen: together at Arthur D. Little

Stephen: together at Columbia University

×3Stephen: together at Beam Therapeutics

About

Stephen Knight is a Yale-trained MD/MBA physician-investor with Bell Labs and NIH roots and biotech operating experience who co-founds platform companies and works with academics to spin out science.

Contact· self-published, not guessed

s•••@fprimecapital.comreveal

Likely email· guessed from name + firm domain, not firm-published

s•••@fprimecapital.comreveal100% confident

Invests in

BiotechCrypto & Web3FintechHealthtechMedical Devices

Board director at Ensoma

Intro paths

→

In turn, Stephen can intro founders to Ensoma's investors below.

Ensoma's investors · 14

5AM VenturesBoston · $100K – $4M checks · since 2023 Aju IB Invesment CorporationSeoul · since 2021 AlexandriaPasadena · since 2023 Arix BioscienceLondon · since 2023 Bill & Melinda Gates FoundationSeattle · since 2023 Bioluminescence VenturesSan Francisco · since 2023 Catalio Capital ManagementNew York · since 2023 Catalio Capital Management, LPNew York · since 2021 Delos CapitalCambridge · since 2023 F-Prime CapitalCambridge · $3M – $10M checks · since 2023 Solasta VenturesBoston · since 2023 SymBiosisBentonville · since 2023 Takeda VenturesCambridge · $1M – $5M checks · since 2023 Viking Global InvestorsStamford · since 2023

Board director at Sana Biotechnology

Intro paths

→

In turn, Stephen can intro founders to Sana Biotechnology's investors below.

Sana Biotechnology's investors · 8

American Family VenturesBoston · $250K – $10M checks ARCH Venture PartnersChicago · $50K – $250M checks · since 2018 F-Prime CapitalCambridge · $3M – $10M checks Flagship PioneeringCambridge · $500K – $10M checks · since 2018 Innovating CapitalNew York · $10K – $3M checks JDRF T1D FundBoston Manta Ray VenturesLondon OUP (Osage University Partners)Bala Cynwyd · $1M – $20M checks

Co-founders at Sana Biotechnology

Richard MulliganDirector

Hans BishopDirector

Board director at Beam Therapeutics

Intro paths

→

In turn, Stephen can intro founders to Beam Therapeutics's investors below.

Beam Therapeutics's investors · 8

ARCH Venture PartnersChicago · $50K – $250M checks · since 2018 Dreamers VCEl Segundo · $500K – $5M checks · since 2018 Eight Roads VenturesMumbai · $5M – $30M checks · since 2018 F-Prime CapitalCambridge · $3M – $10M checks · since 2018 Foresite CapitalWest Hollywood · since 2018 GV (Google Ventures)Mountain View · $250K – $50M checks · since 2018 HongShan Capital GroupHong Kong · $100K – $50M checks · since 2018 OUP (Osage University Partners)Bala Cynwyd · $1M – $20M checks · since 2018

Co-founders at Beam Therapeutics

David R. LiuFounder and Inventor

J. Keith JoungFounder and Inventor

Feng ZhangFounder and Inventor

David R. Liu, Ph.D.Founder and Inventor

J. Keith Joung, M.D., Ph.D.Founder and Inventor

Feng Zhang, Ph.D.Founder and Inventor

Experience

F-Prime Capital (formerly Fidelity Biosciences)President & Senior Managing Partnercurrent2003 — presentCambridge, MA
EPIX PharmaceuticalsPresident, COO1996 — 2003Cambridge, MA
Arthur D. LittleConsultant1991 — 1996Cambridge, MA
AT&T Bell LaboratoriesResearcher1985Murray Hill

Skills & more

Pharmaceutical Industry3Mergers & Acquisitions1

From Stephen's professional profile.

Investments

Board seats

Ensoma

Investor

Aerium TherapeuticsAtalanta TherapeuticsBlueprint Medicines EnsomaGenomicsLeyden LabsParadigmPrime Medicine Quantum Circuits

Sources: SEC Form D filings · curated public sources.

Colleagues at F-Prime Capital

Abby Wagner

Senior Accountant at F-Prime Capital Partners

Abdul Abdirahman

Principal at F-Prime Capital Partners

Alex Pasteur

Partner at F-Prime Capital Partners

Allan Galper

Vice President & Associate General Counsel at F-Prime Capital Partners

Allison MacLeod

Venture Partner at F-Prime Capital Partners

Amber Cai

Venture Partner at F-Prime Capital Partners

Amrit Jalan

Investor at Fine Structures Ventures

Andrew Bognanni

Director of Finance at F-Prime Capital Partners

Network2

Jenny RookeMentee

Managing Director at Genoa Ventures

Eli Casdin

Chief Investment Officer and Founder at Casdin Capital

Investors connected to Stephen in public investor directories — a warm-intro map.

Frequently asked questions

Who is Stephen Knight?: Stephen Knight is a Yale-trained MD/MBA physician-investor with Bell Labs and NIH roots and biotech operating experience who co-founds platform companies and works with academics to spin out science.
Where does Stephen Knight work?: Stephen Knight is President and Managing Partner at F-Prime Capital and Board director at Ensoma and Board director at Sana Biotechnology and Board director at Beam Therapeutics.
What does Stephen Knight invest in?: Stephen Knight invests in Biotech, Crypto & Web3, Fintech, Healthtech, Medical Devices.
What check size does Stephen Knight write?: Stephen Knight typically writes checks of $100K – $10M.
What boards does Stephen Knight sit on?: Stephen Knight holds tracked board seats at Ensoma.
What companies has Stephen Knight invested in?: Investments tracked here include Aerium Therapeutics, Atalanta Therapeutics, Blueprint Medicines, Ensoma, Genomics, Leyden Labs, Paradigm, Prime Medicine, Quantum Circuits.
Where did Stephen Knight go to school?: Stephen Knight studied at Yale School of Medicine (MD); Yale School of Management (MBA); Columbia University (BS, Biology).